The CVS Health Foundation said last week that it has formed a partnership with the Campaign for Tobacco-Free Kids (CTFK) through the “Making the Next Generation Tobacco-Free” program, which will provide grants to organizations implementing health strategies to reduce youth tobacco use and exposure to secondhand smoke. Read More »
Findings of an updated Visante study prepared for the Pharmaceutical Care Management association revealed proposed Maximum Allowable Cost (MAC) restriction could increase the costs of affected generic drugs by up to 56 percent. Read More »
Rite Aid and Envision Pharmaceutical Services (EnvisionRx) said on Wednesday that they have reached a final agreement in which Rite Aid will purchase EnvisionRX, a transaction valued at approximately $2 billion. Read More »
The Senior Care Pharmacy Coalition (SCPC) on Wednesday endorsed the MAC Transparency Act, a new bipartisan bill introduced by U.S. Read More »
Catamaran Corp. will launch a new clinical outcomes-based program for hepatitis C. Read More »
The Any Willing Pharmacy bill (HR 793), supported by the drugstore lobby, would limit access to lower-cost, preferred pharmacies under Medicare Part D and increase Medicare spending by $21 billion in the next 10 years, the Moran Company's research said. Read More »
Amgen said on Wednesday that its Biologics License Application (BLA) for talimogene laherparepvec will be reviewed by the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and the Cellular, Tissue and Gene Therapies Advisory Committee. Read More »
The Alliance to Prevent the Abuse of Medicines recently said the group supports the Obama administration’s proposed budget item to fund efforts toward the prevention and reduction of prescription drug abuse. Read More »
Cumberland Pharmaceuticals said on Wednesday that it is entering a Phase II development program for Boxaban (ifetroban), an oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). Read More »
Pfizer said on Friday that the U.S. Food and Drug Administration has agreed to review the New Drug Application (NDA) for ALO-02, an abuse-deterrent opioid for chronic pain. Read More »
Novartis said on Friday that the U.S. Food and Drug Administration (FDA) granted priority review designation to LCZ696, a test drug for the treatment of heart failure with reduced ejection fraction (HFrEF). Read More »
The U.S. Generic Drug Market Outlook 2018 recently revealed a steadily growing market for generics Read More »
A recent study from the U.S. Centers for Disease Control and Prevention (CDC) has found a decline in the efficacy of the flu vaccine against the virus during the 2014-2015 season. Read More »
The U.S. Food and Drug Administration on Feb. 13 approved Lenvima (lenvatinib) to as a treatment for patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite radioactive iodine therapy. Read More »
The U.S. Food and Drug Administration released five new draft documents last week on compounding and repackaging to help commercial entities comply with important public health laws. Read More »
Teva Pharmaceutical announces the launch of generic Lovenox (enoxaparin sodium injection) in the U.S. Read More »
Recent data from the annual Truven Health Analytics U.S. Benchmarks and Trends reports for employers and health plans predict that employee out-of-pocket costs will experience double-digit growth, and commercial-payer costs will grow at a more modest rate. Read More »
TeaserMcKesson Corporation announced Tuesday that Bansi Nagji was appointed executive vice president of corporate strategy and business development; his predecessor, Brian Tyler, was promoted to president of North American Pharmaceutical Distribution and Services.HeadlineMcKesson appoints Bansi Nagji to succeed Brian Tyler as president of corporate strategy and business developmentBody Prior to McKesson, Nagji led the U.S. Read More »
A commentary published Friday on the HealthAffairs.org blog raises concerns about the possible impact of new cholesterol drugs on the U.S. health care system. Read More »
The FDA's plan to let generic drug companies update their labels showed new signs of life this week. Read More »
Alerts Sign-up